

Prevalence of Multi-Drug Resistant and Extensively Drug-Resistant *Salmonella enterica* Serovar Typhi Recovered from Pediatrics' Septicemia Patients in Lahore

ALIA BATOOL¹, NAMRA YUNUS¹, ASMA YAQOUB¹, DURRE SHAHWAR LONE¹, ANAM KHALID¹, HASAN EJAZ² MUHAMMAD USMAN QAMAR³, QASIM AHMED¹

¹Department of Pathology, Fatima Memorial Hospital College of Medicine and Dentistry, Lahore, Pakistan

²Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf, Saudi Arabia.

³Department of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, 38000, Pakistan

Correspondence to Dr. Muhammad Usman Qamar, Email: musmanqamar@gcuf.edu.pk, Mobile No. +92 301 3054705

ABSTRACT

Background: Increasing antimicrobial resistance to enteric pathogens like *Salmonella* Typhi is an important public health issue.

Aim: To report the prevalence of MDR and XDR *S.* Typhi in the pediatrics population.

Methods: This retrospective study on blood cultures provided an insight into the frequency and drug susceptibility of *S.* Typhi at Fatima Memorial Hospital, Lahore. Blood samples (1-4ml) were drawn from suspected septicemia children's patients (n=2575) aseptically. Blood was inoculated in BacT/Alert peads bottles and processed in an automated BacT/Alert system. Positive samples were further sub-cultured on blood and MacConkey agar. Isolates confirmation and antibiogram were performed by VITEK 2 compact system.

Results: Out of 2575, 292 (11.3%) blood cultures yielded bacterial growth. Among these, *S.* Typhi (170; 58.2%) and *Salmonella paratyphi*A (12; 4.1%) were isolated. *S.* Typhi (43%) was mostly isolated in the age group of 1-5 years. The majority of the *S.* Typhi and *S. paratyphi* A were isolated from peads OPD (55; 30.1%) and peads emergency wards (49; 26.7%). Overall, 23.5% and 54% were MDR and XDR *S.* Typhi respectively, and were sensitive to azithromycin and carbapenems. *S.* Typhi displayed resistance to chloramphenicol (72%), ampicillin (78%), co-trimoxazole (78%), ciprofloxacin (59%), and ceftriaxone (56%).

Conclusion: A strict surveillance plan is mandatory for the containment of the MDR and XDR spread. Public awareness, improved sanitation, safe water supply, and vaccination can play a major role in the prevention of outbreaks.

Keywords: Children, Septicemia, MIC, XDR, *Salmonella* Typhi

INTRODUCTION

Antimicrobial resistance (AMR) is becoming a serious concern around the globe. By 2050, one person will die after every three seconds due to AMR pathogens¹⁻³. *Salmonella* is listed as antibiotic resistance 'priority pathogen' by the World Health Organization (WHO). Typhoid fever caused by the host-restricted bacterial pathogen; *Salmonella enterica* subsp. *enterica* serovar Typhi (*S.* Typhi) represents a potential threat to public health in low- and middle-income countries such as Pakistan⁴. Typhoid infections are estimated to cause more than 200,000 deaths annually around the world⁵.

According to the WHO, typhoid is a major public health issue and has the greatest impact on children and young adults⁶. Pakistan has the third-highest typhoid rate among the global population and the fourth most common cause of death. The incidence of typhoid fever among children between 2-5 years was 573.2 per 100,000 people per year in Pakistan⁷. The infection caused by *S.* Typhi is critical for treatment because of the acquisition of resistant genes primarily mediated by transmissible plasmids. Multi-resistant *S.* Typhi (MDR-*S.* Typhi) was identified between 1970-1980, which showed resistance to first-line drugs (ampicillin, chloramphenicol, co-trimoxazole) and were

susceptible to quinolones⁸. However, the Aga Khan University in Pakistan has documented that during the period 2001-2006, the incidence of MDR-*S.* Typhi increased from 34.2% to 48.5% and resistance to ciprofloxacin also raised from 1.6% to 64.1%⁹. As a result, a third-generation cephalosporin (ceftriaxone) has been widely practiced to treat infections caused by such pathogens. But in 2016, the first case of extensively drug-resistant *S.* Typhi (XDR-*S.* Typhi) was reported in Sindh Province, Pakistan.

The *S.* Typhi (H58 strains) were resistant to all first-line antibiotics, ciprofloxacin, and ceftriaxone, but were sensitive to azithromycin, imipenem, and meropenem¹⁰. A survey in Pakistan found 69% of XDR-*S.* Typhi from Karachi and 27% from Hyderabad¹¹. Consequently, there is a significant risk of a sporadic rise in XDR-*S.* Typhi in other cities of Pakistan. So, this study was aimed to determine the prevalence of MDR and XDR-*S.* Typhi in Lahore, Pakistan.

MATERIALS AND METHODS

Ethical approval was obtained from the Institutional Review Board, Fatima Memorial Hospital, Lahore. Blood samples (n=2575) were collected aseptically from suspected pediatric sepsis patients in BacT/Alert PF blood culture bottles between September 2018 and February 2019. Blood culture bottles were placed in the BacT/Alert automatic blood culture system (BioMerieux, France) for up to five days. Each patient's demographic data such as age, gender was also considered in this study.

Received on 03-01-2021

Accepted on 28-03-2021

All positive blood cultures were then subcultured on Blood and MacConkey agars and incubated at 37°C for 18-24 hours. Preliminary identification of isolates was made by colony morphology, cultural characteristic, and Gram staining. Also, the biochemical confirmation of bacteria was made by GN cards in the compact VITEK 2 system (BioMerieux, France).

The serotypes of Salmonella were determined by an agglutinating antiserum (Bio-Rad, Hercules, California, USA) based on the Kauffmann and White scheme. Briefly, a small drop of antiserum (20µL) was added to a glass slide and mixed with the Salmonella colony. After 5 - 10 seconds, a positive reaction was considered as a visible agglutination, whereas a negative reaction was considered homogenous milky turbidity (Kauffmann-White scheme).

MIC (µg/mL) was determined against different antibiotics (Ampicillin, Ceftriaxone, Chloramphenicol, Ciprofloxacin, Amoxicillin/Clavulanic Acid, Imipenem, Meropenem, Trimethoprim/Sulfamethoxazole) using AST cards by VITEK 2 compact system (BioMerieux, France). Manual antimicrobial susceptibility testing was performed for azithromycin (15 µg)(Oxoid, UK) using the Kirby–Bauer disc diffusion method because they were unavailable in the sensitivity panel for the Gram-negative in VITEK 2 compact system. The zones' sizes were interpreted using CLSI 2018 guidelines.

RESULTS

Of the 2,575 blood cultures, 292(11.3%) resulted in clinically important pathogens. Of that number, 182/292 (62.3%) were *Salmonella spp.*, Among these, 170(93%) isolates were identified as *S. Typhi* and 12(7%) were

S.paratyphi A. Serotypes were also confirmed for *S. Typhi* O9, 12, and *S. paratyphi* O1, 2, 12. The highest number of Salmonella (158; 87%) was found in pediatrics' age groups between 1 - 15 years of age compared to adults where incidence was observed (24;13%). Among children, the highest number of *Salmonella enterica* was isolated from age groups between 1 - 5 years (78; 43%) and 6 to 10 years (58; 32%) (Table-I).

Table-I: Age-wise distribution of *S. Typhi* and *S.paratyphi A* in blood samples

Age Ranges	n; %
< 1 Year	4 ; 2%
1 - 5 years	78 ; 43%
6 -10 years	58 ; 32%
11 -15 years	18 ; 10%
16 -20 years	6 ; 3%
21-25 years	6 ; 3%
> 25 years	12 ; 7%

Most cases of *S. Typhi* and *paratyphi A* were isolated from peads OPD wards (55; 30.1%), followed by peads emergency (49; 26.7%), peads surgical wards (32; 17.6%), peads medical wards (31; 17%), surgical intensive care unit (ICU) (15; 8%) and peads ICU (11; 6%).

Antimicrobial susceptibility testing revealed that 72%, 78%, and 78% of *S. Typhi* were resistant to chloramphenicol, ampicillin, and co-trimoxazole, respectively. Resistance to ciprofloxacin was 59% and ceftriaxone 56%. All isolates tested for azithromycin were susceptible. *S. paratyphi A* was 100% sensitive to all first- and second-line drugs analyzed (Table-II).

Table-II: Percent resistant pattern of *S. Typhi* and *S. paratyphi A*

Isolates	AMP	SXT	C	CIP	CRO	AMC	IMP	MEM	AZT
<i>Salmonella Typhi</i> (n=170)	78%	78%	72%	59%	56%	53%	2%	1%	0%
<i>Salmonella paratyphi A</i> (n=12)	0%	0%	0%	0%	0%	0%	0%	0%	0%

AMP; Ampicillin, SXT; Co-trimoxazole, C; Chloramphenicol, CIP; Ciprofloxacin, CRO; Ceftriaxone, AMC; Amoxicillin/clavulanic acid, IMP; Imipenem, MEM; Meropenem, AZT; Azithromycin

DISCUSSION

Enteric fever is a major public health concern globally. It is a significant burden on morbidity and mortality, particularly in developing countries. The increase in MDR and emerging strains of XDR in Pakistan has created an alarming situation concerning antibiotic resistance¹². There are few studies available on the XDR *S. Typhi* in Lahore. Therefore, the purpose of this study was to determine the regional antibiotic susceptibility profile of *S. Typhi* in Lahore. In this study, 182 (62.3%) *S. Typhi* isolates were identified from 292 positive blood cultures over a short six-month period, indicating a higher incidence of typhoid fever than in recent years. Various studies documented *S. Typhi* as the most common serotype isolated over the past decade and similar results were observed in our study (*S. Typhi* =93% and *S. paratyphi A*=7%)¹³⁻¹⁵.

As the literature indicated the highest incidence of typhoid in children under the age of 15 years, 87% of this study population also came from the pediatric age group. In our study, the incidence of MDR *S. Typhi* was 23.5%, while another study carried out by Ali *et al.* also showed similar

results at a rate of 37.5%¹⁶. The cause of MDR may be attributed to the misuse of over-the-counter available antimicrobials and their uncontrolled use without appropriate medical supervision. In terms of XDR *S. Typhi*, the frequency was 54% in our study, while another study conducted by Hussain *et al.* showed a similar result with 48%¹⁷. Even though antibiotics are life-saving medications, their excessive use may limit the effectiveness of this antimicrobial agents¹⁸. A resurgence of MDR *S. Typhi* has been observed on this subcontinent. Almost all first-line antibiotics showed complete resistance in many instances. In this study, resistance to ampicillin, chloramphenicol, and co-trimoxazole was 78%, 72%, and 78%, respectively. The study by Lin-Hui Su *et al.* showed upward trends in resistance to ampicillin (91%), chloramphenicol (91%), and co-trimoxazole (88%). Ceftriaxone and ciprofloxacin were considered to be the main pillars of typhoid therapy, but we also found high resistance to these antibiotics. Resistance to ciprofloxacin was observed in 59% of isolates, but increased resistance to ciprofloxacin from 1% to 69% was observed in a tertiary care hospital in Taiwan¹⁹.

Another study from Pakistan reported 69% XDR *S. Typhi* in Karachi and 27% in Hyderabad, Sindh¹¹. Our study has depicted worrisome data of these MDR and XDR strains in Punjab province. 71% of the isolates in the study were MDR strains and 54% were XDR strains of *S. Typhi*. This means that, like Sindh, Punjab is also facing a frightening increase in resistant strains of *Salmonella*. A recent study conducted in India by Makkar A *et al.* found 2.73% and 1.91% multi-resistant *S. Typhi* and paratyphi respectively which is significantly less than our study²⁰. Another study by Florian *et al.* predicted a higher incidence of MDR *S. Typhi* in Ghana, Kenya, and Tanzania²¹. Azithromycin is one of the few remaining treatment options to deal with these superbugs. A study by Misra R *et al.* revealed high susceptibility of 92% and 92.6% in two different Indian cities²². Another study by Divyashree *et al.* also reported 93.6% susceptibility to azithromycin²³. However, all isolates analyzed in this study were sensitive to azithromycin. As azithromycin is an effective oral option available for typhoid fever, its broad use in a variety of other clinical conditions should be minimized to prevent the potential emergence of resistant strains.

CONCLUSION

Our study indicated that children under the age of 5 years were primarily impacted by XDR *S. Typhi*. Meropenem and azithromycin, alone or in combination, were the most efficient antibiotics for the treatment of XDR *S. Typhi*. Generalized antibiotic stewardship programs need to be conducted and a strict surveillance plan is required to control this spread and formulate an antibiotic stewardship policy. Public awareness, improved sanitation, drinking water supply, and mass vaccination can play an important role in the prevention of epidemics.

Acknowledgment: The authors would like to thank the Department of Pathology, Fatima Memorial Hospital, for supporting the study.

Conflict of interest: All authors declared no conflict of interest.

REFERENCES

1. Qamar MU, Hassan B, Khurshid M, Shafique M, Atif Nisar M, et al. The present danger of New Delhi metallo- β -lactamase: a threat to public health. *Future microbiology*. 2020;15:1759-78.
2. Younas S, Ejaz H, Zafar A, Ejaz A, Saleem R, Javed H. AmpC beta-lactamases in *Klebsiella pneumoniae*: An emerging threat to the paediatric patients. *J Pak Med Assoc*. 2018;68(6):893-7.
3. Javed H, Ejaz H, Zafar A, Rathore AW. Metallo-beta-lactamase producing *Escherichia coli* and *Klebsiella pneumoniae*: A rising threat for hospitalized children. *J Pak Med Assoc*. 2016;66(9):1068-72.
4. Gibani MM, Britto C, Pollard AJ. Typhoid and paratyphoid fever: a call to action. *Curr Opin Infect Dis*. 2018;31(5):440.
5. Kurtz JR, Goggins JA, McLachlan JB. *Salmonella* infection: Interplay between the bacteria and host immune system. *Immunol Lett*. 2017;190:42-50.
6. Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AKM. Challenges and Opportunities for Typhoid Fever Control: A Call for Coordinated Action. *Clin Infect Dis*. 2016;62(Suppl 1):S4-S8.
7. Akram J, Khan AS, Khan HA, Gilani SA, Akram SJ, Ahmad FJ, et al. Extensively Drug-Resistant (XDR) Typhoid: Evolution, Prevention, and Its Management. *BioMed Research International*. 2020;2020:6432580.
8. Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic Resistance and Typhoid. *Clin Infect Dis*. 2019;68(Suppl 2):S165-S70.
9. Hasan R, Zafar A, Abbas Z, Mahraj V, Malik F, Zaidi A. Antibiotic resistance among *Salmonella enterica* serovars Typhi and Paratyphi A in Pakistan (2001-2006). *Journal of infection in developing countries*. 2008;2(4):289-94.
10. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an Extensively Drug-Resistant *Salmonella enterica* Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins. *mBio*. 2018;9(1):e00105-18.
11. Yousafzai MT, Qamar FN, Shakoor S, Saleem K, Lohana H, Karim S, et al. Ceftriaxone-resistant *Salmonella Typhi* Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine. *Clin Infect Dis*. 2019;68(Suppl 1):S16-S21.
12. Radhakrishnan A, Als D, Mintz ED, Crump JA, Stanaway J, Breiman RF, et al. Introductory Article on Global Burden and Epidemiology of Typhoid Fever. *Am J Trop Med Hyg*. 2018;99(3_Suppl):4-9.
13. Khanal B, Sharma SK, Bhattacharya SK, Bhattarai NR, Deb M, Kanungo R. Antimicrobial susceptibility patterns of *Salmonella enterica* serotype typhi in eastern Nepal. *J Health Popul Nutr*. 2007;25(1):82-7.
14. Wasfy MO, Frenck R, Ismail TF, Mansour H, Malone JL, Mahoney FJ. Trends of Multiple-Drug Resistance among *Salmonella* Serotype Typhi Isolates during a 14-Year Period in Egypt. *Clinical Infectious Diseases*. 2002;35(10):1265-8.
15. Eng S-K, Pusparajah P, Ab Mutalib N-S, Ser H-L, Chan K-G, Lee L-H. *Salmonella*: A review on pathogenesis, epidemiology and antibiotic resistance. *Frontiers in Life Science*. 2015;8(3):284-93.
16. Moradali MF, Ghods S, Rehm BH. *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front Cell Infect Microbiol*. 2017;7:39.
17. Hussain A, Satti L, Hanif F, Zehra NM, Nadeem S, Bangash TM, et al. Typhoidal *Salmonella* strains in Pakistan: an impending threat of extensively drug-resistant *Salmonella Typhi*. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology. 2019;38(11):2145-9.
18. Javaid H, Zafar A, Ahmed JM, Ejaz H, Zubair M. Changing patterns of antimicrobial susceptibility of *salmonella Typhi* at the children's hospital Lahore. *Pak J Med Health Sci*. 2012;6(1):201-4.
19. Lee CJ, Su LH, Huang YC, Chiu CH. First isolation of ciprofloxacin-resistant *Salmonella enterica* serovar Typhi in Taiwan. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2013;46(6):469-73.
20. Makkar A, Gupta S, Khan ID, Gupta RM, Rajmohan KS, Chopra H, et al. Epidemiological Profile and Antimicrobial Resistance Pattern of Enteric Fever in a Tertiary Care Hospital of North India - a Seven Year Ambispective Study. *Acta medica (Hradec Kralove)*. 2018;61(4):125-30.
21. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. *Nature Communications*. 2018;9(1):5094.
22. Mishra SV, Gayen A, Haque SM. COVID-19 and urban vulnerability in India. *Habitat Int*. 2020;103:102230-.
23. Sjölund-Karlsson M, Joyce K, Blickenstaff K, Ball T, Haro J, Medalla FM, et al. Antimicrobial susceptibility to azithromycin among *Salmonella enterica* isolates from the United States. *Antimicrob Agents Chemother*. 2011;55(9):3985-9.